David Silberman
Known title: Chief Financial OfficerCIK: 0001867998
Associated companies
Transaction History
| CGEN | ▲ Buy | Grant | 19,500 | $0 | 7/29/2026 | View on chart |
| ORMP | ▲ Buy | Grant | 136,500 | — | 1/4/2024 | View on chart |
| ORMP | ▲ Buy | Grant | 24,500 | — | 5/26/2023 | View on chart |
| ORMP | ▲ Buy | Grant | 97,500 | — | 4/17/2023 | View on chart |
| ORMP | ▲ Buy | Grant | 39,000 | — | 7/28/2022 | View on chart |
| ORMP | ▲ Buy | Grant | 19,000 | — | 1/3/2022 | View on chart |
| ORMP | ▲ Buy | Grant | 50,000 | $0 | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Compugen to Host Virtual KOL Event on COM701
Compugen announced it will host a virtual event on October 5, 2026, to discuss its COM701 program in ovarian cancer and updates on the Unigen platform. This event is relevant as it provides a platform for the company to share scientific data with key opinion leaders. The stock currently trades below its average analyst target, with technical indicators showing it is near support levels.
Compugen to Host Virtual KOL Event on COM701. Compugen announced it will host a virtual event on October 5, 2026, to discuss its COM701 program in ovarian cancer and updates on the Unigen platform. This event is relevant as it provides a platform for the company to share scientific data with key opinion leaders. The stock currently trades below its average analyst target, with technical indicators showing it is near support levels.